FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

导出原文传递

翻译打印收藏纠错

作者： de Claro, R. Angelo ^[1] ; McGinn, Karen M. ^[2] ; Verdun, Nicole ^[3] ; Lee, Shwu-Luan ^[4] ; Chiu, Haw-Jyh ; Saber, Haleh ; Brower, Margaret E. ; Chang, C. J. George ; Pfuma, Elimika ; Habtemariam, Bahru ; Bullock, Julie ; Wang, Yun ; Nie, Lei ; Chen, Xiao-Hong ; Lu, Donghao (Robert) ; Al-Hakim, Ali ; Kane, Robert C. ; Kaminskas, Edvardas ; Justice, Robert ; Farrell, Ann T. ; Pazdur, Richard

作者单位： US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Silver Spring, MD USA ^[1] US FDA, Ctr Drug Evaluat & Res, Off Biostat, Silver Spring, MD USA ^[2] US FDA, Ctr Drug Evaluat & Res, Off New Drug Qual Assessment, Silver Spring, MD USA ^[3] US FDA, Ctr Drug Evaluat & Res, Off Hematol & Oncol Prod, Off New Drugs, Silver Spring, MD USA ^[4]

发布时间 2015-12-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Clinical cancer research

2015年21卷16期

3586-3590页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除